Get started
Vericel CorporationVericel CorporationVericel Corporation

Vericel Corporation

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

VCEL chart


Full chart

VCEL upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪2.07 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
223.46
Basic EPS (TTM)
0.21 USD
Net income (FY)
‪10.36 M‬ USD
Revenue (FY)
‪237.22 M‬ USD
Shares float
‪49.61 M‬
Beta (1Y)
1.11

Employees


Employees (FY)
357
Change (1Y)
+43 +13.69%
Revenue / Employee (1Y)
‪664.49 K‬ USD
Net income / Employee (1Y)
‪29.03 K‬ USD

About Vericel Corporation


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Dominick C. Colangelo
Website
vcel.com
Headquarters
Cambridge
Founded
1989
FIGI
BBG000BDCM24
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

VCEL news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as VCEL.

Frequently Asked Questions


The current price of VCEL is 42.02 USD — it has increased by 0.41% in the past 24 hours. Watch Vericel Corporation stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Vericel Corporation stocks are traded under the ticker VCEL.
VCEL stock has fallen by −0.53% compared to the previous week, the month change is a −9.78% fall, over the last year Vericel Corporation has showed a −13.21% decrease.
We've gathered analysts' opinions on Vericel Corporation future price: according to them, VCEL price has a max estimate of 72.00 USD and a min estimate of 51.00 USD. Watch VCEL chart and read a more detailed Vericel Corporation stock forecast: see what analysts think of Vericel Corporation and suggest that you do with its stocks.
VCEL reached its all-time high on Sep 24, 1997 with the price of 1,590.00 USD, and its all-time low was 1.69 USD and was reached on Nov 17, 2015. View more price dynamics on VCEL chart.
See other stocks reaching their highest and lowest prices.
VCEL stock is 4.49% volatile and has beta coefficient of 1.11. Track Vericel Corporation stock price on the chart and check out the list of the most volatile stocks — is Vericel Corporation there?
Today Vericel Corporation has the market capitalization of ‪2.07 B‬, it has decreased by −7.39% over the last week.
Yes, you can track Vericel Corporation financials in yearly and quarterly reports right on TradingView.
Vericel Corporation is going to release the next earnings report on May 7, 2025. Keep track of upcoming events with our Earnings Calendar.
VCEL earnings for the last quarter are 0.38 USD per share, whereas the estimation was 0.32 USD resulting in a 18.89% surprise. The estimated earnings for the next quarter are −0.13 USD per share. See more details about Vericel Corporation earnings.
Vericel Corporation revenue for the last quarter amounts to ‪75.38 M‬ USD, despite the estimated figure of ‪76.51 M‬ USD. In the next quarter, revenue is expected to reach ‪53.84 M‬ USD.
VCEL net income for the last quarter is ‪19.81 M‬ USD, while the quarter before that showed ‪−901.00 K‬ USD of net income which accounts for ‪2.30 K‬% change. Track more Vericel Corporation financial stats to get the full picture.
No, VCEL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 15, 2025, the company has 357 employees. See our rating of the largest employees — is Vericel Corporation on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Vericel Corporation EBITDA is ‪10.02 M‬ USD, and current EBITDA margin is 4.23%. See more stats in Vericel Corporation financial statements.
Like other stocks, VCEL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Vericel Corporation stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Vericel Corporation technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Vericel Corporation stock shows the sell signal. See more of Vericel Corporation technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.